Streck is pleased to announce an expanded partnership with Ceres Nanosciences (Ceres) to distribute the Nanotrap Extraction Advanced Technology (NEAT) Liquid Biopsy Kit – Streck BCT worldwide. The NEAT Liquid Biopsy Kit – Streck BCT is formulated to capture, concentrate and extract cfDNA from plasma samples isolated from Streck blood collection tubes.
“Streck is excited to launch another innovative product from our strategic partner Ceres,” said Matthew Kreifels, vice president of Sales, MarCom, and Business Development at Streck. “The NEAT Liquid Biopsy Kit creates efficiencies and results our customers will find invaluable when used in combination with Streck stabilization solutions.”
With liquid biopsy, cancer researchers have the power to identify critical biomarkers from a few milliliters of blood. However, these biomarkers can be in very small amounts, and when blood samples begin to degrade and release proteins and nucleic acids that can obscure the concentrations of biomarkers of interest, isolation becomes even more difficult. Combined use of Streck Cell-Free DNA BCT and Nucleic Acid BCT with the NEAT Liquid Biopsy Kit ensures that samples remain the same from collection to analysis and that the cfDNA isolated from these samples for downstream analysis is high yield and high purity.
“Ceres looks forward to seeing Streck’s innovative customers use the NEAT Liquid Biopsy Kit and Streck blood collection tubes to push the frontiers of liquid biopsies,” said Robbie Barbero, Ph.D., chief business officer at Ceres Nanosciences.
Performance characteristics of Cell-Free DNA BCT have only been established on the Guardant360 CDx assay. Nucleic Acid BCT and NEAT Liquid Biopsy Kit – Streck BCT are for Research Use Only. Not for use in diagnostic procedures. Nucleic Acid BCT should only be used for research or in the development of new assays.
